The company is a province level development center for anti-infection drugs. The company is proud to have a highly professional research team and capable of new product development and process optimization. The company has developed class 4 new drugs such as Linglanxin, cefetamet pivoxil, azithromycin lactobionate, compounded amoxicillin, Yizuoxin, Yitixin and class 2 drugs such as quinapril hydrochloride, itopride hydrochloride in collaboration with famous research institutes. Three class 1 drugs are under development now. All these increased Harbin Pharma’s competitiveness and ability to face future challenges as an “aircraft carrier” of the Chinese pharmaceutical industry.